Fig. 1.

Patient no. 2 received three therapies with ¹³¹I-MIP-1095. Staging before and after each therapy was conducted with PSMA ligand PET/CT (¹²⁴I-MIP-1095 and ⁶⁸Ga-PSMA-11). The first two therapies reduced the tumor burden. However, the third therapy didn’t show a sufficient effect. The last two pictures on the right side show the rapid progress between September and November. The images of the PET scans show the maximum intensity projections, those of the therapies show the geometric mean of the gamma-ray co-emission which enables imaging during therapy